QUICKLINKS AND VIEW OPITONS
Belviq (lorcaserin) side effects: Upper respiratory infection 13.7% of patients, 12.3% with placebo
Saturday, June 22, 2013 2:30 pm Email this article
Upper respiratory tract infection was reported in 13.7% of patients given the weight loss drug, Belviq (lorcaserin), versus 12.3% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.
Belviq (lorcaserin hydrochloride) Prescribing Information. Revision 08/2012.
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.